Urology · Bladder Cancer
Bladder Cancer Assessment & Treatment
Expert cystoscopy, TURBT and specialist management for bladder cancer in London. Consultant-led care from diagnosis through to treatment, with same-day haematuria investigations available.
Understanding Bladder Cancer
Most bladder cancers are transitional cell carcinomas (TCC/urothelial carcinoma) arising from the cells lining the bladder. Blood in the urine — visible or microscopic — is the most common presenting symptom and always warrants investigation.
Other symptoms include urgency, frequency and burning on urination. Risk factors include smoking (the most significant modifiable risk), occupational chemical exposure and chronic bladder irritation.
Most bladder cancers are non-muscle-invasive (NMIBC) at diagnosis — highly treatable with endoscopic surgery. Muscle-invasive disease (MIBC) requires more aggressive treatment and close coordination with oncology colleagues.
Visible or painless blood in the urine is a red flag that should never be assumed to be benign without proper investigation. Early diagnosis gives the best possible outcomes.
— Mr Torath Ameen, FRCS (Urol)Diagnosing Bladder Cancer
A prompt and thorough assessment is essential when haematuria is present. Mr Ameen offers same-day haematuria investigations where possible, including flexible cystoscopy at the initial consultation.
Rapid Haematuria Assessment
Same-visit or next-day investigation for patients with visible blood in the urine.
Flexible Cystoscopy
Direct visualisation of the bladder lining under local anaesthetic — the definitive diagnostic test for bladder cancer.
CT Urogram
Cross-sectional imaging of the kidneys, ureters and bladder to assess the entire urinary tract.
MDT-Based Staging
Urine cytology, NMP22 testing and multidisciplinary team review to accurately stage all newly diagnosed tumours.
TURBT Under General Anaesthetic
Transurethral resection of bladder tumour — both diagnostic confirmation and therapeutic removal of the tumour.
BCG Immunotherapy Coordination
Intravesical BCG programme arranged and supervised for eligible high-risk NMIBC patients.
Treatment Options for Bladder Cancer
Treatment is tailored to tumour stage, grade and individual patient factors. The large majority of bladder cancers are non-muscle-invasive and can be effectively managed without bladder removal.
Non-muscle-invasive bladder cancer (NMIBC)
TURBT is the primary treatment for NMIBC — the tumour is removed endoscopically through the urethra with no external incisions. Pathological analysis of the specimen determines grade and depth of invasion, guiding further management.
Intravesical BCG immunotherapy is instilled directly into the bladder following TURBT for intermediate and high-risk disease. A standard course involves weekly instillations for six weeks, with maintenance BCG at 3, 6 and 12 months for high-risk tumours.
Intravesical chemotherapy (mitomycin C) is an alternative to BCG for intermediate-risk disease, or used as a single post-TURBT instillation to reduce recurrence. Risk stratification using the EORTC scoring system guides the choice of adjuvant treatment. Most patients with NMIBC are cured or well controlled with endoscopic treatment alone.
Muscle-invasive bladder cancer (MIBC)
Radical cystectomy — surgical removal of the bladder — is the standard curative treatment for muscle-invasive disease, performed in coordination with the oncology and reconstructive urology team. Neoadjuvant cisplatin-based chemotherapy is given prior to surgery where the patient is fit enough.
Radical radiotherapy with concurrent chemotherapy offers a bladder-sparing alternative for selected patients who are unsuitable for or prefer to avoid surgery. Outcomes in specialist centres are comparable to cystectomy for well-selected cases.
Mr Ameen coordinates closely with oncology colleagues through the multidisciplinary team (MDT) for all cases of muscle-invasive and locally advanced disease. Palliative treatment options are discussed sensitively where appropriate for advanced or metastatic bladder cancer.
Recovery & Ongoing Care
After TURBT
Day case or overnight stay depending on tumour complexity. A urinary catheter is left in place for 24–48 hours. Most patients return to normal activities within 1–2 weeks. The first surveillance cystoscopy is arranged at 3 months to check for early recurrence.
BCG Therapy
Weekly intravesical instillations for six weeks. Maintenance BCG follows at 3, 6 and 12 months for high-risk disease. Flu-like symptoms and bladder irritation are common side effects. BCG immunotherapy is highly effective at preventing recurrence and progression in high-grade NMIBC.
Surveillance Programme
Regular follow-up cystoscopy — 3-monthly initially, then 6-monthly, then annually — depending on risk category. Urine tests are performed between cystoscopies. CT imaging monitors the upper urinary tract. Mr Ameen provides a written surveillance plan at every appointment.
Bladder Cancer FAQs
Concerned about blood in the urine? Act promptly.
Visible haematuria is always a red flag. Mr Ameen offers rapid assessment across his London clinics.